Clinical Trial

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Name: Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma — clinical trial record (NCT07546630)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-04-16.

Trial Details

NCT Number	NCT07546630
Lead Sponsor	Affiliated Hospital to Academy of Military Medical Sciences
Conditions	Relapsed/Refractory B-Cell Lymphoma
Enrollment	20 participants
Start Date	2026-04-30
Primary Completion	2028-05-01 (estimated)
Study Completion	2029-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-29